Non-Clinical Evidence Requirements in the Ethiopian Medical Device Dossier

1. Key takeaways

Chapter 3 of the Ethiopian non-IVD dossier divides non-clinical evidence into ten individually assessable items: physical and mechanical characterization; chemical and material characterization; electrical systems (safety, mechanical and environmental protection, and electromagnetic compatibility); radiation safety; software and firmware; biocompatibility and toxicological evaluation; non-material-mediated pyrogenicity; safety of biological source materials (human or animal); sterilization validation; and animal testing. In addition, the chapter covers non-clinical literature and shelf life and packaging verification (product stability and packaging verification). Assessing applicability item by item and stating the basis for each judgement is the compiling method of this chapter.

The ten items are not ten mandatory test reports. They form a decision list: for each item, the manufacturer either submits the corresponding report or explains why the item does not apply to the device. Sterilization validation belongs only to sterile products; electrical safety and electromagnetic compatibility belong only to active devices; biological source material safety belongs only to products containing human or animal materials. This item-by-item logic is what reviewers expect, and blank entries or silent omissions are treated as defects rather than as decisions.

The chapter also connects to two supporting frameworks. Section 3.3 provides the standards entry, backed by the EFDA recognized standards list published online on July 17, 2026, and Sections 3.6.1 and 3.6.2 separate product stability from packaging verification, so that shelf-life claims rest on two independent but complementary bodies of evidence.

2. Legal basis

3. Expert insights

Insight 1: the ten non-clinical study items are an item-by-item determination, not a full submission. The chapter structure is a determination checklist: for each study, a report is submitted where the item applies, and a reason is stated where it does not. Only sterile products need sterilization validation; only active devices need electrical safety and electromagnetic compatibility; only products containing biological source materials need the corresponding safety evaluation. Manufacturers who treat the list as a menu to justify rather than a form to fill save substantial effort, provided every negative determination is written down with a technical reason tied to the device design.

Insight 2: electrical safety and electromagnetic compatibility are merged into a single item. The full wording of Section 3.4.3 is electrical systems: safety, mechanical and environmental protection, and electromagnetic compatibility. This shows that the authority treats the safety requirements of the IEC 60601 series and the electromagnetic compatibility requirements as one integrated evidence block. In practice this means the EMC test report should be submitted together with the electrical safety report, under the same dossier item and with a common index, rather than scattered across the submission, and deviations from particular clauses of the family should be declared once, in one place.

Insight 3: pyrogenicity is subdivided into non-material-mediated pyrogenicity. Section 3.4.7 lists non-material-mediated pyrogenicity separately from biocompatibility. This corresponds to pyrogenic risks other than those mediated by materials, and sterile and implantable products must pay particular attention to it. The distinction matters operationally: biocompatibility testing under the ISO 10993 framework addresses contact-mediated responses, while non-material-mediated pyrogenicity addresses, for example, endotoxin introduced through water systems or processing. Devices that are sterile but not patient-contacting in the usual sense can still require this evaluation.

Insight 4: shelf life and packaging verification are listed as an independent item. Section 3.6 contains product stability and packaging verification. These are independent of sterilization validation: sterilization validation demonstrates that the sterilization process is effective, while packaging verification demonstrates that the sterile barrier remains intact throughout the shelf life. A sterile product therefore needs all three elements aligned to the same claimed expiry date, and the stability data must cover the labelled shelf life stated on the labelling, otherwise a mismatch will surface as a query.

Insight 5: the standards entry and the recognized standards list together form the methodological basis. Section 3.3 establishes a dedicated standards item, and the authority published the recognized standards list in July 2026. Adopting versions listed in the recognized list markedly reduces the probability of review queries; adopting standards outside the list or older versions requires an equivalence justification. Each non-clinical study item should name the standard and version applied, so the reviewer can map every test report to a recognized method without hunting through annexes.

4. Practical recommendations

1. Assess applicability item by item across the ten study categories: state reasons for non-applicable items and leave nothing blank.
2. Prepare electrical safety and electromagnetic compatibility together: organize them under the IEC 60601 series.
3. For sterile products, prepare sterilization validation and packaging verification in parallel: the two cannot substitute for each other.
4. For implantable and sterile products, carry out the non-material-mediated pyrogenicity evaluation.
5. Prefer current versions within the EFDA recognized standards list: and state the version used.
6. Ensure product stability data cover the claimed shelf life: consistent with the labelling.

5. Verification checklist

• □ Applicability has been assessed item by item under Sections 3.4.1–3.4.10
• □ Written reasons have been given for non-applicable items
• □ Active devices have submitted electrical safety and electromagnetic compatibility evidence
• □ Sterile products have submitted sterilization validation and packaging verification
• □ The standards adopted have been stated under Section 3.3 and checked against the recognized list
• □ Product stability data cover the shelf life stated on the labelling

Regulatory information verified as of October 29, 2026. The non-clinical evidence items and standards basis listed in this article are based on the current text of Chapter 3 of EFDA/GDL/097 Version 002 and the EFDA recognized standards list; when the list is updated, they must be re-checked.

• Ethiopia local resource: GRZAN can assist manufacturers from the Chinese mainland and overseas with marketing authorization (MA), Certificate of Competency (CoC) and import licence applications to the Ethiopian Food and Drug Authority (EFDA), including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization application and re-registration, applicability determination for the low-risk notification procedure, Essential Principles conformity justification, labelling and IFU localization (English), and vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.